Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular Lymphoma
Preliminary analysis of data from the EPCORE™ NHL-2 study demonstrates patients with previously untreated follicular lymphoma (FL) who received epcoritamab in... Read more.
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
First and only EGFR inhibitor and targeted treatment to show benefit in Stage III setting, extending progression-free survival by more than three years... Read more.
CatalYm Reports Impressive and Lasting Responses Including Multiple Complete Responses in Heavily Pretreated, Late- to Last-Line Metastatic NSCLC, Urothelial and Hepatocellular Cancer Patients Treated with Visugromab/Nivolumab Combination
The results include data from three main study cohorts: In the non-squamous non-small cell lung cancer (NSCLC) cohort, an Objective Response Rate (ORR) for NSCLC... Read more.
Stronger Than Ever: Adani Portfolio Delivers Record Performance
45% EBITDA growth in FY24, EBITDA reaches USD 10 Bn Adani Portfolio EBITDA increased to USD 10 Bn, up by record 45% Y-o-Y 84% of EBITDA is through “Core Infrastructure”... Read more.
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma
DREAMM-8 phase III trial showed statistically significant and clinically meaningful improvement in primary endpoint of progression-free survival (PFS) Median PFS... Read more.
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from... Read more.
Tempus Introduces New HER2 & FOLR1 Testing Solutions to Support Personalized Patient Care
CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, announced new testing solutions to help physicians identify... Read more.
ZT Systems Announces ACX200 Solutions Featuring NVIDIA GB200 Grace Blackwell Superchips for Next-Generation Accelerated Computing
Rack-Level ZT Platform Powered by NVIDIA GB200 Grace Blackwell Superchips Enables Trillion-Parameter Inference and Training for Generative AI SECAUCUS, N.J.–(BUSINESS... Read more.
Denodo Integrates NVIDIA NIM Inference Microservices to Accelerate and Optimize AI Capabilities for Enterprises
Integration enhances the Denodo Platform, providing enterprise customers with faster, more secure, and fully scalable AI capabilities PALO ALTO, Calif.–(BUSINESS... Read more.
Denodo Opens ME Regional Head Office in Kingdom of Saudi Arabia to Meet Growing Demand for Data Management and AI
At the office opening today, Ángel Viña, CEO of Denodo will be joined by Dr. Shaikha Dheya Bint Ebrahim Al Khalifa and representatives from Google Cloud RIYADH,... Read more.